CPLD 2005 FFC vs Respondent M16

Facts
The French Cycling Federation (Fédération Française de Cyclisme, FFC) charges respondent M18 for a violation of the Anti-Doping Rules. During a cycling event on June 9, 2004, respondent provided a sample for doping test purposes. Analysis of the samples showed the presence of triamcinolone which is a prohibited substance according the World Anti-Doping Agency (WADA) prohibited list.

History
The respondent claims that the positive result derived from an ointment, containing glucocorticosteroids, he had used. The panel accepted this explanation and regarded this treatment as medical justifiable.

Decision
1. The respondent is acquitted.
2. The decision will not be published.
3. The decision will be sent to the parties involved.

Original document

CPLD 2005-16 (AS).pdf

Parameters

Legal Source
National Decisions
Date
7 March 2005
Original Source
French Anti-Doping Agency (AFLD)
Country
France
Language
French
ADRV
Adverse Analytical Finding / presence
Legal Terms
Acquittal
Sport/IFs
Cycling (UCI) - International Cycling Union
Other organisations
Agence Française de Lutte contre le Dopage (AFLD) - French Anti-Doping Agency
Conseil de Prévention et de Lutte contre le Dopage (CPLD) - Council to Prevent and Counteract Doping
Fédération Française de Cyclisme (FFC) - French Cycling Federation
Laboratories
Paris, France: Agence Française de Lutte contre le Dopage (AFLD)
Doping classes
S9. Glucocorticosteroids
Substances
Triamcinolone
Medical terms
Legitimate Medical Treatment
Document type
Pdf file
Date generated
13 November 2014
Date of last modification
3 December 2014
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin